However, systemic administration of anti-PD1 Abs does not enhance therapeutic efficacy against CNS-localized GBM, potentially due to the BBB preventing Abs from entering the CNS, thus preventing Abs engagement with CAR T cells at the tumor site. This evidence concerns the gene PDCD1 and neoplasm.